Interim results from the ongoing Phase II dose-escalation study were presented at the 2009 Annual Meeting of American Society of Clinical Oncology.
Cynthia Sullivan, President and CEO, said: “Targeted radiation therapy is well suited for solid cancers, such as pancreatic cancer, and our data, though limited, corroborate this notion.”
“In light of the fact that there aren’t many viable treatment options for patients with advanced pancreatic cancer, we believe clivatuzumab tetraxetan labeled with yttrium-90 is in a good position to become the first radioimmunotherapeutic agent for pancreatic cancer therapy, and we currently intend to develop it through commercialization on our own,” she added.